drugset / Trial / NCT01933048

Self-Administered Nasal Influenza Feasibility Study

NCT01933048

RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group self-administration of LAIV.

Timeline

Start
2012-09
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine Intranasal

Indications